CN114945564A - Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法 - Google Patents

Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法 Download PDF

Info

Publication number
CN114945564A
CN114945564A CN202180008769.6A CN202180008769A CN114945564A CN 114945564 A CN114945564 A CN 114945564A CN 202180008769 A CN202180008769 A CN 202180008769A CN 114945564 A CN114945564 A CN 114945564A
Authority
CN
China
Prior art keywords
complex
arb
metabolite
nep inhibitor
exp3174
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202180008769.6A
Other languages
English (en)
Other versions
CN114945564B (zh
Inventor
许文杰
李松
程冲
孙晶超
华怀杰
颜杰
陈涛
周世强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Publication of CN114945564A publication Critical patent/CN114945564A/zh
Application granted granted Critical
Publication of CN114945564B publication Critical patent/CN114945564B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

提供ARB代谢产物与NEP抑制剂的复合物新晶型及其制备方法。

Description

PCT国内申请，说明书已公开。

Claims (15)

  1. PCT国内申请，权利要求书已公开。
CN202180008769.6A 2020-01-19 2021-01-18 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法 Active CN114945564B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010059820 2020-01-19
CN2020100598203 2020-01-19
CN202010823402 2020-08-17
CN2020108234027 2020-08-17
PCT/CN2021/072414 WO2021143898A1 (zh) 2020-01-19 2021-01-18 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法

Publications (2)

Publication Number Publication Date
CN114945564A true CN114945564A (zh) 2022-08-26
CN114945564B CN114945564B (zh) 2023-06-30

Family

ID=76863638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180008769.6A Active CN114945564B (zh) 2020-01-19 2021-01-18 Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法

Country Status (2)

Country Link
CN (1) CN114945564B (zh)
WO (1) WO2021143898A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027779A1 (zh) * 2022-08-04 2024-02-08 深圳信立泰药业股份有限公司 ARNi化合物新晶型及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098689A (zh) * 2005-11-09 2008-01-02 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
WO2017125031A1 (zh) * 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法
CN113286789A (zh) * 2019-05-30 2021-08-20 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101098689A (zh) * 2005-11-09 2008-01-02 诺瓦提斯公司 血管紧张素受体拮抗剂和nep抑制剂的药物组合产品
WO2017125031A1 (zh) * 2016-01-20 2017-07-27 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物及其制备方法
CN113286789A (zh) * 2019-05-30 2021-08-20 深圳信立泰药业股份有限公司 血管紧张素ii受体拮抗剂代谢产物与nep抑制剂的复合物的新用途

Also Published As

Publication number Publication date
CN114945564B (zh) 2023-06-30
WO2021143898A1 (zh) 2021-07-22

Similar Documents

Publication Publication Date Title
EP3317281B1 (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
CN101891738B (zh) 达沙替尼多晶型物及其制备方法和药用组合物
JP2020100624A (ja) Ｌ−オルニチンフェニルアセテートおよびその製造方法
CN111936467B (zh) 作为c-Met激酶抑制剂的化合物的结晶及其制备方法和用途
CN114945564A (zh) Arb代谢产物与nep抑制剂的复合物新晶型及其制备方法
KR20200030107A (ko) 무정형 형태의 빌란테롤 트리페나테이트 및 이의 제조방법
CN107980038A (zh) 沙库巴曲钙盐
CA3136599A1 (en) Voruciclib poly morphs and methods of making and using thereof
Fandiño et al. Mechanochemical synthesis of a novel eutectic of the antimicrobial nitazoxanide with improved dissolution performance
US20080234286A1 (en) Stable amorphous imatinib mesylate and production process therefor
WO2019033969A1 (zh) 替米沙坦与氢氯噻嗪的共晶
US20220251091A1 (en) Amorphous umbralisib monotosylate
JP2012131786A (ja) 活性医薬成分の結晶形態
WO2024027779A1 (zh) ARNi化合物新晶型及其制备方法与应用
JP2019089822A (ja) トピロキソスタットの新規結晶形及びその製造方法
KR20170012332A (ko) [2-[1-(6-메틸-3-피리다지닐)-4-피페리디닐]에톡시]-3-에톡시-1,2-벤즈이속사졸의 무수 결정성 유리 염기 형태
RU2684278C1 (ru) Фумарат пиридиламина и его кристаллы
WO2019086509A1 (en) Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor
WO2018078383A1 (en) Pharmaceutical composition comprising amorphous selexipag
CN112174833B (zh) 盐酸埃他卡林a晶型及其制备方法
US20230286938A1 (en) Polymorphs of a dihydroorotate dehydrogenase (dhod) inhibitor
AU2020224678B2 (en) Solid polymorphs of a FLNA-binding compound and its hydrochloride salts
WO2023078424A1 (zh) Kras突变体抑制剂的晶型、其制备方法及其应用
CN108929269A (zh) 苄异喹啉类非去极化肌松剂及其制备方法和用途
WO2021016929A1 (zh) 恶拉戈利与乙胺嘧啶的共晶型a及其制备方法和用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017

Applicant after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Address before: 518040 37th floor, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province

Applicant before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

GR01 Patent grant
GR01 Patent grant